Skip to main content
. 2021 Sep 8;6(17):e132585. doi: 10.1172/jci.insight.132585

Figure 7. M3R-specific antagonist darifenacin ameliorated cerulein-induced AP.

Figure 7

(A). Schema of treatment with darifenacin hydrobromide (DH) (20 mg/kg; ip), an M3R-specific antagonist. (B) DH treatment reduced cerulein-induced pancreas edema in C57/BL6 (WT) mice. (C) Serum amylase was lower in DH-treated mice (n = 8 mice/group) than saline-treated group. (D). DH treatment improved pancreatitis histology (scale bar: 200 μm). (E). CD11b inflammatory cells were reduced upon DH treatment (scale bar: 200 μm). *P 0.05 and #P 0.01, DH group vs. vehicle group. Two-tailed unpaired Student’s t test.